

Company presentation

Updated October 2024

Disclaimer

The information in this presentation has been prepared by Lifecare (the “Company”). This presentation does not constitute a recommendation regarding any securities of the Company. By accepting to attend this presentation and/or receive this information, you agree to be bound by the following limitations and provisions:

This presentation has been prepared based on information available as of the date hereof. No representation or warranty (expressor implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company, or any advisor or any such persons’ officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this presentation. The Company is in its early stages of development and is considered to be a venture company. Venture companies in general entail a high degree of risk. It is highly recommended that potential investors seek further advice of risks associated with venture investments in general, and in particular specific risks for the Company. The information herein is subject to change, completion, supplements or amendments without notice. By relying on this presentation, you accept the risk that the presentation does not cover matters that could have been disclosed, have a more comprehensive investigation been carried out.

The presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof and may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. It should be understood that subsequent developments may affect the information contained in this document, which neither the Company nor its advisors are under an obligation to update, revise or affirm.

This complete presentation is for informational purposes only and does not constitute an offer to sell shares in of the company. This presentation is not a prospectus, disclosure document or offering document and does not purport to be complete.

This presentation has not been reviewed or approved by any regulatory authority or stock exchange. The (re)distribution of this presentation and/or any prospectus or other documentation into jurisdictions other than Norway may be restricted by law. This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to acquire any securities offered by any person in any jurisdiction in which such an offer or solicitation is unlawful. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such restrictions.

The presentation and any purported liability in connection with it is subject to Norwegian law and is subject to the exclusive jurisdiction of the Norwegian courts.


Company presentation

Market & competition

Lifecare's Sencell sensor

Clinical studies and progress


About Lifecare



A Global Crisis that Remains Uncontrolled

Diabetes Diagnosis and Cost

Adults (aged 20-79) with Diabetes Globally



Source: IDF Atlas, 10th edition (2021)


Global Diabetes Related Health Expenditures



Glucose Monitoring

Standard treatment

Blood Glucose Meter



State-of-the art treatment

Continuos Glucose Monitor



Sensing principles – Continuous Glucose Monitoring

1

Glucose oxidase

Dexcom (G6 & G7), Medtronic, Abbott
(FreeStyle Libre 2 & 3)

Longevity: 7- 14 days
Annual cost: \$ 1.500 – 4.000



2

Flourescence

Senseonics (Eversense)

Longevity: 180 days
Annual cost: \$ 6.000





3

Osmotic pressure


Lifecare (Sencell)

Longevity: 172 days (in-vitro)
Annual cost: >\$ 2.000 (assumption)






Clinical stage sensor company
developing the worlds smallest
Continuous Glucose Monitor



LIFECARE

Sencell system

- ✓ Size of a grain of rice
- ✓ Injected under the skin
- ✓ 6 months longevity
- ✓ No calibration needed



Clinical status



Study «LFC-SEN-001» – concluded May 2023
presented at American Diabetes Association Scientific Sessions June 23

Purpose:


Collect human proof-of-concept performance data for algorithm development during meal experiments and for further device optimization

Conclusion:


Subcutaneous glucose concentrations was tracked in a manner comparable as the Libre 2 or Dexcom G7 needle sensors.

Clinical accuracy – Consensus error grid (ISO 15197: BG meters)

Results in zone A and B:
regulatory accepted



LFC-SEN-001: Retrospective
consensus error-grid analysis





Zone A	237	90.8%
Zone B	24	9.2%
Zone C	0	0%
Zone D	0	0%
Zone E	0	0%
n=261		

Documented 12 weeks longevity in live tissue


Ongoing longevity study at in cooperation with the Veterinary institute at the Norwegian University of Life Sciences.

Implant in dog has shown 12 weeks functionality with no complications during the period or after explanation.


Bacteriological examination and biopsy confirm that no unexpected foreign body reactions occurred.






One technology



Two markets



The potential of Lifecare in the veterinary market



Number of dogs & cats that develop diabetes every year

Product development agreement with Sanofi



Sanofi-Avenis Group sponsor the development program for miniaturizing the Sencell Glucose sensor with funding of EUR 290.000 based on completion of defined development phases



The Development Agreement is **based on a robust evaluation and due diligence process** from Sanofi scientists and business department, including a detailed review of the product development plan and the commercial aspects of Lifecare's Sencell Glucose relative to Sanofi's product portfolio and the competitive landscape





Sanofi is entitled to a “first right of refusal” to negotiate an exclusive and worldwide distribution license of Lifecare technology and IP for glucose monitoring.

Progress

	Studies	Regulatory compliance	Production and market launch
2022	<p>Successful in-vitro testing confirming functionality of miniaturized sensors</p> <p>Proof-of-concept in humans</p>	<p>Approval for accuracy study LFC-SEN-001</p>	<p>Production location secured</p>
2023	<p>In-human study (LFC-SEN-001) confirming clinical accuracy in line with gold standard</p> <p>Longevity study of the Sencell sensor with operational lifetime of more than 172 days</p>	<p>ISO 9001 and ISO 13485 certified</p> <p>Norwegian Medicine Agency confirms no specific regulation for Sencell sensor medical device for animals in Norway</p> <p>Approval for longevity study in dogs (LFC-SEN-002)</p>	<p>Preparations for automated production</p>
2024	<p>In-dogs longevity study (LFC-SEN-002) confirming operational lifetime</p> <p>Preparations for LFC-SEN-003</p>	<p>Expect to receive approval for clinical study LFC-SEN-003</p> <p>CE approved device to remove subdermal implants</p>	<p>Pilot production</p> <p>Automated production</p> <p>Product launch for veterinary market</p>



From pilot to automated production





Mainz: manufacturing facilities for volume production

Organization



Lifecare ASA
(Bergen, NO)



Lifecare Laboratory
(Mainz, DE)



Lifecare
NanoBioSensors
(Reutlingen, DE)



Lifecare Chemistry
(Bristol UK)



Lifecare Veterinary
(Bergen, NO)



RemovAid
(Lysaker, NO)

People



Full-time equivalents: 33




PhD: 7



Scientific workers: 23



PhD-students: 4



LIFECARE